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The human cytochrome P450 3A4 mono-oxygenates ∼50% of all drugs. Its substrates/products enter/leave
the active site by access/exit channels. Here, we perform steered molecular dynamics simulations, pulling the
products temazepam and testosterone-6 OH out of the P450 3A4 enzyme in order to identify the preferred
substrate/product pathways and their gating mechanism. We locate six different egress pathways of products
from the active site with different exit preferences for the two products and ﬁnd that there is more than just
one access/exit channel in CYP3A4. The so-called solvent channel manifests the largest opening for both
tested products, thereby identifying this channel as a putative substrate channel. Most channels consist of one
or two π-stacked phenylalanine residues that serve as gate keepers. The oxidized drug breaks the hydrophobic
interactions of the gating residues and forms mainly hydrophobic contacts with the gate. We argue that product
exit preferences in P450s are regulated by protein-substrate speciﬁcity.
1. Introduction
Cytochrome P450 3A4 (CYP3A4) is the major drug-
metabolizing enzyme in humans, affecting more than 50% of
all swallowed drugs.1 CYP3A4 catalyzes mono-oxygenation
reactions such as hydroxylation and epoxidation.2 The so-formed
products are more hydrophilic and hence are more easily
excreted from the body. CYP3A4 oxidizes a variety of chemical
compounds and drugs with different sizes and shapes.3,4 The
active site is located at the hydrophobic core of the protein and
is connected to the surface of the enzyme through access
channels (Figure 1).5 The prosthetic heme group in the active
site is covalently bound to a conserved cysteine and is
responsible for substrate oxidation. The substrate oxidation
process follows a well-characterized catalytic cycle.6-8 The cycle
is initiated when a substrate enters the active site and removes
a water molecule coordinated to the ferric heme. The heme’s
iron shifts to its high-spin state, thereby facilitating the reduction
of the ferric center by NADPH-cytochrome P450 reductase.
Following molecular oxygen consumption and subsequent
addition of two electrons from the reductase and two protons
from the surrounding, the O-O bond is cleaved, and an active
species is formed that oxygenates the substrate. Subsequently,
the product leaves the active site through the access channels,
and the enzyme resumes its resting state. Although the extent
of sequence identity of the cytochrome P450 family of enzymes
(P450s) is rather low, their structure is conserved9 with one
available fold for P450s in SCOP.10 The most variable regions
in P450s are the substrate recognition sites (SRSs)11,12 that
spatially form the active site and access channels. This variability
could account for the different substrate speciﬁcity manifested
by different P450 isoforms. Wade et al.13 identiﬁed a structurally
conserved channel in all bacterial P450s positioned between the
FF′ loop,  1, and  4 sheets and termed it 2a (Figure 1); yet,
interestingly, using molecular dynamics (MD) and repulsive
expulsion molecular dynamics, they also showed that in three
different bacterial P450s, the gating mechanism for ligand exit
through channel 2a is different and depends on the speciﬁc
isoform.14 This difference can modulate protein-substrate
speciﬁcity in P450s. In contrast to bacterial P450s, in mam-
malian P450s that are anchored to the endoplasmatic reticulum
(ER) membrane, channel 2a is predicted to face the hydrophobic
ER membrane, suggesting that highly hydrophobic substrates
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Figure 1. CYP3A4 structure including substrate channel 2a (shown
in blue). The enzyme is represented in cyan cartoons, FF′ loop and F′
helix (connected to G′ helix in cyan) colored red, and  1 sheet colored
orange. The heme prosthetic group is represented as white VDW
spheres.
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Published on Web 09/03/2009will reach the active site via this channel. Thus, substrate
speciﬁcity is inﬂuenced not only by interactions at the P450
active site but also by the properties of the access routes to the
binding site such as their size, shape, and physicochemical
properties.
In most available CYP3A4 crystal structures, the enzyme
exists in a closed state with little difference between the ligand-
bound and -unbound enzyme conformations.15,16 However, in
the two latest determined X-ray structures of CYP3A4 com-
plexed with two large inhibitors (ketoconazoles) and a substrate
(erythromycin) inside of the active site,17 the enzyme undergoes
a large conformational change. The active site expands by 80%
of its volume compared to that of the unbound structures, and
there is a large shift in the F′G′ helices region (Figure 1) due to
ligand binding. An extreme shift of this region was observed
in the mammalian CYP2B4 crystal structure.18 It is expected
that the substrate/product entrance/exit will induce conforma-
tional changes that are not observed in most CYP3A4 crystal
structures. Previous theoretical studies on bacterial P450s,13,14,19
mammalian P450s,20-24 and other related heme-containing
enzymes25,26 were carried out in order to monitor ligand egress
from the enzyme’s active site. MD simulations on mammalian
P450s resulted in different dominant egress pathways that either
expressed different substrate speciﬁcity of the P450 isoforms
or stemmed from the different ligand probes tested in the
simulations.
Here, using MD and steered MD (SMD), we simulated the
last step of the catalytic cycle pulling out of the human CYP3A4
active site two distinct products, temazepam (TMZ) and
testosterone-6 OH (TST-OH) (Figure 2). We searched for all
physically feasible pathways for product egress, their dimen-
sions, and the key residues involved in the gating mechanism
and compared the results to previous simulations of other P450
isoforms. We then attempted to predict the preferred product
exit routes in CYP3A4, seeking the factors that determine this
preference. We expect that the substrate channel characteriza-
tion, achieved in this work for CYP3A4, will provide further
insight into the biophysics of transport to (from) the enzyme.
2. Computational Methods
Setting up the System. The CYP3A4 structure was taken
from the PDB27 (code 1TQN15). Missing residues of 1TQN were
modeled with InsightII (http://www.accelrys.com/products/). pKa
values were calculated using the MCCE28 software with DelPhi29
as a Poisson-Boltzmann solver with a dielectric constant of 4.
Hydrogen atoms were added with CHARMM.30 The structure
was solvated in a cubic box of ∼21000 TIP3P31 water molecules,
in addition to crystallographic waters in order to apply periodic
boundary conditions. Chloride ions were added to neutralize
the system. The structures of TMZ and TST-OH were derived
from their substrate structures, diazepam and testosterone, taken
from the Cambridge structural database (http://www.ccdc.cam.
ac.uk/products/csd/, codes DIZPAM10 and TESTOM01, re-
spectively). We substituted the oxidized C-H groups in
diazepam and testosterone with C-OH groups. We took into
account the ﬂexibility of the TMZ phenyl ring by generating
several conformations using the systematic search algorithm of
the Cerius2 software. Each TMZ conformer and TST-OH were
geometrically docked to the CYP3A4 active site using the
PatchDock32 software, taking into account shape complemen-
tarity. The TMZ ﬂexibility was addressed by including different
orientations of its rotatable phenyl ring in the docking procedure.
Docking solutions with a distance less than 3 Å between the
product hydroxyl and the heme’s iron were considered for
further steps. The remaining solutions were minimized by the
CHARMM software, and the lowest CHARMM energy docking
solution was used as a starting point for further MD simulations.
Force Field Parameters. Heme and protein parameters were
taken from CHARMM2233 and CHARMM2734 force ﬁelds,
respectively. Fe and S related missing parameters were added
from Autenrieth et al.35 and Bathelt et al.36 The heme’s atoms’
partial charges were calculated by a QM(B3LYP)/MM optimi-
zation at the DFT level of theory, with a sextet multiplicity as
the ground state.37 The basis sets used were an effective core
potential (ECP) and the LACVP for the iron and 6-31G for the
rest of the heme and C442 atoms. The heme Mulliken charges
were added to the force ﬁeld. The QM/MM calculation used
the ChemShell package.38 The force ﬁeld parameters for TMZ
were taken from a previous diazepam force ﬁeld39 with the
addition of the hydroxyl moiety. TST-6OH and -16OH param-
eters were derived from a previously published CHARMM force
ﬁeld for cholesterol.40 TMZ and testosterone products’ atomic
partial charges were modiﬁed to account for the addition of the
hydroxyl group by a QM/MM optimization as done with the
heme.
MD Procedure. For each run, the system was initially
minimized with CHARMM, with a decreasing harmonic force
constraint on the enzyme. Further procedures were performed
using the NAMD code.41 The minimized system was gradually
heated up to 310 K and equilibrated for 50 ps. The equilibrated
system was then run for 500 ps of MD simulation followed by
a 1.6 ns of steered MD (SMD42) pulling each product out of
the active site. We applied a canonical NVT ensemble dynamics
a t3 1 0Kw i t ha1f stime step. The Shake algorithm was applied
to ﬁx all bond lengths involving hydrogen atoms. A ﬁnal
nonbonded interaction cutoff radius was 12 Å, with a switching
function starting from 10 Å. Nonbonded electrostatic interactions
were calculated with Particle Mesh Ewald summation.43 Snap-
shots were saved each 500 steps. The SMD procedure used a
pulling spring force constant of 7 kcal/mol/Å2 with a constant
velocity of 0.000025 Å/fs. The chosen force constant and pulling
velocity were three times larger and twice slower than those
applied in previous SMD simulations of the human CYP3A4.22
The pulling force was applied after the equilibration phase, with
the spring connected between the center of mass of the product
and a “dummy” atom in the general direction of the channels
exit. Three channels (2b, 2e, and the solvent channel, termed
S; see Figure 3) are observed to be partially open in the PDB
ﬁle 1TQN, which we used as input.15 Therefore, the directions
of the SMD pulling forces in the case of the above channels
were determined according to the visible channel exit. For those
channels that evaded detection, 18 different vectors were tested
that are in the general direction of the roof and sides of the
active site, and three additional channels were detected (see
Figure 2. Chemical structures and carbon numbering systems for the
CYP3A4 products temazepam (TMZ) and testosterone-6OH (TST-
OH).
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starting point structures are available in the Supporting Informa-
tion (SI).
In addition to the SMD simulations in the presence of a
product, we performed a substrate-free 1.6 ns of classical MD
simulation on CYP3A4.
3. Results
Global CYP3A4 Stability. We performed different SMD
runs to ﬁnd the minimum constant velocity and force constant
values that ensure low protein ﬂuctuations but permit the escape
of the product from the active site. We ended up with 12
different SMD simulations (6 distinct channels for each product)
and another SMD run of TST-160H escaping through channel
2c (see Discussion). A velocity of 0.000025 Å/fs was found as
a minimum cutoff. As judged from the total energy, pressure,
rmsd, and RMSF proﬁles (Figures S1-S4, Supporting Informa-
tion), the entire system and protein structure appeared stable
throughout the simulations, even when further applying an
external pulling force. The average CR rmsd’s along all of the
CYP3A4-unbound, TMZ-bound, and TST-OH-bound simula-
tions were 1.2, 1.2-1.3, and 1.8 Å, respectively, with not more
than (0.1 Å ﬂuctuations (Figure S3, Supporting Information).
Major local ﬂuctuations observed in the unbound dynamics were
in residues 255-270 and 280-290, which comprise a modeled
loop, missing in several PDB ﬁles of CYP3A4.16 In the bound
SMD simulations, ﬂuctuations occur mainly in the TST-OH
simulations and are larger than TMZs. Major RMSF peaks
detected upon addition of the products are at residues 100-125
and 200-250 (Figure S4a-S4d, Supporting Information), which
belong to the BC loop and FG helices’ secondary structure
elements, respectively (Figure 3A). These secondary structures
are known to be the most ﬂexible in P450s.44
Substrate Channels’ Structure and Dimensions. The substrate
exit pathways are named according to Cojocaru et al.’s5
nomenclature and include substrate channels 2a, 2b, 2c, 2e, and
3 and the solvent channel (S) (Figure 3). The channels are
deﬁned according to the secondary structures that form their
entrance/exit (Figure 3A). Channel 2a is located between the
FF′ loop and the  1 and  4 sheets. Channel 2b is positioned
between the F′ and G′ helices and the  1 sheet and the BC
loop. Channel 2c is between the GG′ helices and the BC loop.
Channel 2e is surrounded by the BC loop. Channel 3 passes
through the F′G′ helices, and channel S is above the I helix
and between the FF′ loop and the  4 sheet.
The channel lengths were measured, starting 3 Å above the
heme Fe up to the bottleneck residues that form the gates. The
channels lengths are 19, 18, 17, 12, 17, and 13 Å for 2a, 2b,
2c, 2e, 3, and S channels, respectively. Thus, channels 2e and
S are the shortest paths from the active site to the enzyme
surface. The channels’ bottleneck opening radii were measured
during the simulations using the MolAxis tool that identiﬁes
and calculates channel surfaces within macromolecules by
computational geometry techniques.45 Figure S5 (Supporting
Information) depicts the bottleneck radius of all of the channels
along the simulations, and Table 1 summarizes the channels’
maximum opening radii. We noticed that for both products, the
S channel manifested the largest opening, and substrate channel
2c had the smallest bottleneck radius.
Channel-Product Interactions. Table 2 summarizes the
major residues which interact with the products during
the simulations (Tables S1-S10, Supporting Information, give
secondary structure details and electrostatic interactions). These
residues are derived from contact analysis, taking into account
interactions of less than 5 Å between the product and the
enzyme. The majority of the nonbonded interactions between
the products and the channel-forming residues are hydrophobic
aromatic and hydrophobic aliphatic. In contrast to observations
on the ligand egress in the bacterial P450cam,46,47 for the
CYP3A4, we observe no salt bridge perturbations during product
exit through any of the channels. The two salt bridges located
at channels 2a and 2b between D76-R106 and D76-R372 are
very stable during the exit of both products. Polar and some
hydrophobic residues serve as hydrogen-bond donors and
acceptors that H bond usually the hydroxyl and carbonyl groups
of the products (Table 2, superscript). The active site key
residues that hold the product by hydrogen bonds are S119 and
R212. S119 was experimentally shown to alter testosterone
hydroxylation selectivity.48 Mutations of S119 to hydrophobic
residues switched the 6  to 2  hydroxylation. Thus, the loss of
Figure 3. CYP3A4 secondary structures related to the identiﬁed substrate channels. (A) Secondary structure elements in CYP3A4 that deﬁne the
different channels. FF′ loop, F′ and G′ helices, G helix, I helix, BC loop, and  1 and  4 sheets are colored blue, silver, purple, yellow, black,
orange, and red, respectively. The rest of the enzyme is colored cyan and represented as cartoons. The heme prosthetic group is represented by
white VDW spheres. (B) Substrate channels detected during SMD. Channel surfaces were calculated by MolAxis. Channels 2a, 2b, 2c, 2e, 3, and
S are colored red, blue, yellow, green, orange, and purple, respectively. F′G′ helices are colored silver, and the BC loop is in black. The rest of the
enzyme is colored cyan and represented as cartoons.
TABLE 1: Maximum Bottleneck Values for Each Substrate
Channel Observed for the Egress of TMZ and TST-OH in
Angstroms
channel TMZ TST-OH
2a 3.70 4.14
2b 3.65 3.96
2c 3.09 3.91
2e 3.87 4.20
3 3.31 4.12
S 3.98 4.47
13020 J. Phys. Chem. B, Vol. 113, No. 39, 2009 Fishelovitch et al.the S119 directed hydrogen bond to the substrate by site-speciﬁc
mutations changes the regioselectivity of testosterone oxidation.
Product release from the CYP3A4 active site is initiated by
hydrogen-bond breakage between the product and R212 and
S119 (Tables S7-S10, Supporting Information) and detachment
from hydrophobic residues, I301, F304, A305, F213, A370, and
L482. Overcoming these barriers leads to product movement
toward the gate keeper residues. The products pass the gates of
channels 2a, 2b, 2c, 2e, 3, and S after 900, 800, 1150, 700,
900, and 750 ps, respectively.
Substrate Channels’ Gating Mechanism. The invested total
SMD work (WSMD) during each product egress was measured
every 1 ps according to eq 1
where WSMD is the mechanical work done along a SMD
trajectory, n is the number of MD steps of a trajectory, F b(t)i s
the SMD force invested at time t, D b(t) and D b(t - 1) are the
coordinates of the center of mass of the product at times t and
t - 1, respectively, and θ is the angle between the force and
the product displacement vectors. The calculated total WSMD
values are summarized in Table 3, and the entire SMD work
proﬁles for all simulations are presented in Figure S6 (Sup-
porting Information). Most of these proﬁles have a similar
behavior. At the beginning of the simulations, WSMD increases,
reaching a global maximum that represents the potential barrier
of product release via the channel gate. Following the product
exit, there is usually a fast decline in the work to almost zero.
For TMZ (TST-OH), the largest total WSMD observed was while
exiting from channel S (2c), and the lowest was from channel
2e (2e and 3). In order to test the robustness of our results, we
performed three different SMD runs for each CYP3A4-detected
channel with either TMZ or TST-OH. The TMZ (TST-OH) exit
from the CYP3A4 active site through channels 2a, 2b, and 3
(2c, 2e, and S) was repeated three times. The results presented
similar exit pathways, CR rmsd and SMD work proﬁles (Figures
S7-S9, Supporting Information). In addition, the calculated total
SMD work was similar for each triplicate, with a relative
standard deviation of not more than 3% (Table 3).
In order to deﬁne the gating mechanism of product egress
from the substrate channels, we focused on MD snapshots 250
ps prior to and following the time frame where the maximum
WSMD was observed. From visual inspection, rmsd, and distance
proﬁles, we identiﬁed the gate keepers of each channel for both
products. Figure S10 (Supporting Information) presents the
distance along MD between the two major gating residues of
each channel found for both products. Table 4 summarizes the
gating residues of each channel for both products.
We observe that for channels 2a, 2b, 2c, and 3, the gates
consist of hydrophobic residues, mainly phenylalanine residues.
These residues parallel- or T-shape π-stack with each other,
and the product disrupts this interaction when exiting the
enzyme. This disruption is shown in the sequence of frames in
Figures 4 and 5. In channel 2e, the release of TST-OH resulted
in a breakage of a hydrogen bond between the carbonyl group
of S119 and one of the guanidinium moiety hydrogen atoms of
R105. However, for TMZ, the exit through channel 2e is coupled
to breakage of aliphatic hydrophobic interactions between F108
and I120. This observation is experimentally supported by
F108W and I120W mutations49 that showed higher 1OH over
4OH midazolam (structurally related to TMZ) hydroxylation
compared to the wild-type enzyme. Mutations to tryptophan are
believed to close channel 2e and impose a switching of the
midazolam entrance to another channel that may lead to a
different active site orientation and product formation. In channel
S, we observe interruption of aliphatic interactions between
R212 and L482, while the product escapes the enzyme, as
portrayed in Figure 6.
TABLE 2: Major Channel Forming Residues of Substrate Channels 2a, 2b, 2c, 2e, 3, and S in the CYP3A4 Enzyme Obtained
by Close Contact Analysisa with the TMZ and TST-OH Products
channel channel residues
2a L47b Y53b F57 D76 R105 R106 F108 S119c
R212c F213b,c F215b L216 L221 T224 R372 L482b
2b F57 D76b Q79b,c R105 R106 F108b S119c R212b
F213 F215 F220 T224b P227b A370b R372 L482
2c R105 F108 M114b,c I118 S119b,c I120 R212c F213c
F215 V240 F241c T246b I300c F304c
2e R105b,c F108 G111 K115 I118 S119b,c I120b E122b
R212c F213 F215 V240 A370
3 F108b S119b,c I120 K209c R212c F213b F215 F219
F220 V240 F241 P242 R243 V245c F304b
S S119c K173c L211 R212c F213c E308b T309 S311b
S312b,c I369b A370 M371 L482b L483c Q484c
a Close contacts were deﬁned by product atoms having a distance of less than 5 Å from enzyme residues. b The residue serves as a H-bond
acceptor. c The residue serves as a H-bond donor.
TABLE 3: Total SMD Work (Calculated According to
Equation 1) Done along the TMZ and TST-OH Trajectories
while Exiting through Substrate Channels 2a, 2b, 2c, 2e, 3
and S (Units Are in kcal/mol)
channel TMZ TST-OH
2a 265.0 ( 5.5a 283.2
2b 235.1 ( 7.5a 268.7
2c 292.1 445.4 ( 14a
2e 203.6 244.6 ( 6.9a
3 274.8 ( 8.9a 235.1
S 337.1 276.2 ( 5.8a
a Average of three runs.
WSMD ) ∑
t)1
n
F b(t) × [D b(t) - D b(t - 1)] × cos(θ) (1)
TABLE 4: Gating Residues of Substrate Channels 2a, 2b,
2c, 2e, 3, and S Identiﬁed in the SMD Simulations of TMZ
and TST-OH
channel TMZ TST-OH
2a F57-F215 F57-F215
2b F108-F220 F108-F220
2c F108-F241 F108-F241
2e F108-I120 R105-S119
3 F213-F241 F213-V240
S R212-L482 R212-L482
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nisms, (i) breaking F-F π-stacking; (ii) breaking aliphatic
contacts, as seen at the S channel between R212 and L482; and
(iii) breaking the H bond, as observed in the exit of TST-OH
through channel 2e between R105 and S119. The predominant
mechanism is the π-stacking.
4. Discussion
Dominant Channel in CYP3A4. Of all known P450s, the
isoforms CYP2C9, CYP2D6, and CYP3A4 account for the
vast majority of drug metabolism.3 In the CYP2C9 structure
bound to ﬂurbiprofen,50 the solvent channel was observed to
be relatively open. It was suggested that for the human
CYP2D6, channel S, deﬁned earlier by Haines et al.51 for
the bacterial CYPBM3, is the main substrate access channel.52
Here, TST-OH leaving the active site through channel S
resulted in the largest opening compared to the other channels
with a similar total WSMD to most detected channels (Table
3). Hence, the solvent channel in CYP3A4 is likely to serve
as a substrate/product exit channel as in the human P450
isoforms.
CYP3A4 is tethered to the ER membrane by its N-terminus
and contacts the membrane through other parts of the enzyme,
including the F′G′ loop in the vicinity of substrate channels 2a
and 2b.53 Therefore, channels 2a and 2b are predicted to lie
close to or dip into the ER membrane. TST-OH contains three
hydrophilic positions, and it is less likely that it will exit through
those channels.
It was shown by mutation and kinetic studies that cholesterol,
the precursor of testosterone (TST), enters the microsomal
CYP7A1 through the membrane and interacts with the F′G′ loop
residues.54 Williams et al.53 suggested that lipophilic substrates
and products could enter and exit through the lipid bilayer. As
the exact orientation of channels 2a and 2b with respect to the
membrane is unknown, the exit of TST-OH through channels
2a and 2b cannot be ruled out.
In terms of the invested SMD work, TST-OH was found to
exit through channel 2c with the largest difﬁculty compared to
any other channel and with a thermodynamically favorable
exiting through channels 2e and 3 (Table 3). We therefore
conclude that channel 2c is less likely to serve as a gateway for
testosterone major product in CYP3A4, while channels 2e and
Figure 4. TST-OH release from substrate channel 2a. TST-OH is colored red, heme is in green, and gating residues are in blue. The enzyme is
represented by cyan cartoons. The ﬁgures have the same orientation. The time frames are after (A) 0, (B) 450, and (C) 715 ps from the start of the
simulation.
Figure 5. TMZ release from substrate channel 2b. TMZ is colored red, heme is in green, and gating residues are in blue. The enzyme is represented
by cyan cartoons. The ﬁgures have the same orientation. The time frames are after (A) 10, (B) 400, and (C) 900 ps from the start of the simulation.
Figure 6. TST-OH release from substrate channel S. TST-OH is colored red, heme is in green, and gating residues are in blue. The enzyme is
represented by cyan cartoons. The ﬁgures have the same orientation. The time frames are after (A) 0, (B) 460, and (C) 960 ps from the start of the
simulation.
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channel S was found to be highly ﬂexible. It faces the cytosol
and contains a charged gating residue which could lead the
product out of the CYP3A4 active site.
In contrast to TST-OH, although the egress of TMZ resulted
in a large opening of the S channel, it needed the largest WSMD
compared to the rest of the channels (Table 3). This is accounted
for by a high potential barrier derived from electrostatic
interaction between the positive R212 and the oxygen of the
hydroxyl group of TMZ (Figure S11, Supporting Information).
We observe the lowest work proﬁles when TMZ exits from the
CYP3A4 active site via channel 2e, suggesting that this channel
is preferred for the exit of the hydroxylated product of diazepam.
Thus, there is no one speciﬁc access/exit route for substrates/
products in CYP3A4.
Dominant Channel in P450s. Schleinkofer et al.21 carried
out MD simulations on CYP2C5, which is closely related to
CYP2C9, pulling out of the active site progesterone, 21-
hydroxyprogesterone (PROG-21OH), and benzenesulphona-
mide. The 2c channel was the predominant exit route. Li et
al.20 tested by MD simulations the egress of TST from the
CYP2B1 active site. They found that the 2c channel is one
of the preferred exit pathways for TST, in contrast to our
results of CYP3A4. The differences in these observations
may arise from different substrate speciﬁcities between P450
subfamilies.
We hypothesize that the product outlet pathway is deter-
mined in part by the post-oxidation product orientation inside
of the active site. To test this hypothesis, we pulled TST-
16OH, positioned in a 16 hydroxylation orientation, out of
CYP3A4 from channel 2c. The TST-16OH exit resulted in a
much faster and easier exit than that of TST-6OH, with a
maximum pulling force of about half of that observed for
TST-6OH (Figure S12, Supporting Information). In addition,
the mechanical work measured along the TST-16OH escape
from channel 2c was 189.4 kcal/mol. This easy escape from
channel 2c is in accord with the previous simulations of the
exit of TST-16ROH20 and PROG-21OH21 from CYP2B1 and
CYP2C5, respectively. Both TST-16OH, which is hydroxy-
lated mainly at the TST 16 position55 in CYP2B1, and PROG-
21OH are positioned inside of the active site in the general
direction of channels 2c and 2e exits. However, the major
hydroxylation product of TST by CYP3A4 is the TST-6 OH,
with minor hydroxylation at position 16 (Figure 2),56,57 and
docking it accordingly resulted in a different orientation than
that of TST-16OH and in a favorable orientation for exiting
via channel 3 (Figure S13, Supporting Information).
We therefore conclude that the oxidized position in large
products that have less rotational and translational freedom
inside of the active site can determine the outlet pathway.
Furthermore, there is no single dominant exit pathway for
all P450s, and different products of the same substrate (e.g.,
TST) leave the active site through channels based on the
substrate oxidation speciﬁcity.
Conservation of the Gating Mechanism. We ﬁnd that the
gating residues are bulky and hydrophobic in most CYP3A4
substrate channels (Table 4). Schleinkofer et al.21 pointed to
V106 and K241 in CYP2C5 as the gate keepers of channel 2c.
In contrast, in the channel 2c of CYP3A4, the gating residues
are F108 and F241, despite the fact that the channel faces the
hydrated cytosol. Li et al.20 also observed that channel 2c in
CYP2B1 is gated by two phenylalanine residues. They also
pointed to a phenylalanine residue as the gate keeper of channel
2e in CYP2B1. Winn et al.14 showed that CYPcam channel 2a is
gated by F87 and F193, similar to our predicted gating
mechanism. However, they observed different gating mecha-
nisms for other bacterial P450s that include a positive arginine.
From all of the above and considering that the channels
are part of the variable SRSs regions, the gating mechanisms
are different for corresponding channels in different P450
isoforms. However, the phenylalanine gating mechanism
exists in many P450s, which implies a nonspeciﬁc substrate
channel.
5. Conclusions
We performed SMD simulations on CYP3A4 pulling out
of its active site two products resulting from the hydroxy-
lation of diazepam and testosterone. We identiﬁed several
putative access channels connecting the active site to bulk
solvent. We observed no single dominant channel in CYP3A4.
For both temazepam and testosteron-6 OH, we observed a
thermodynamic preference for exiting through channel 2e.
In addition, testosteron-6 OH showed a low mechanical work
proﬁle while exiting through channel 3, which faces the
cytosol as does channel 2e. The solvent channel was found
to be the most ﬂexible in CYP3A4 and is predicted to be a
substrate/product channel as proposed earlier for other
P450s.52 Moreover, we found that the product shape and
orientation after being oxidized determined the preferred
channel from which it would exit. In the majority of the
channels, the gate keepers are π-stacked phenylalanine
residues; to exit, the product has to break this interaction.
This gating mechanism is not conserved in P450s but exists
in many isoforms and in different channels.
The versatility of the egress mechanism in CYP3A4 makes
perfect sense, considering the fact that this isoform is
promiscuous and oxidizes a great variety of substrates. This
variety requires, in turn, a good number of egress pathways.
We believe that these data will assist in identifying some
structural determinants related to substrate speciﬁcity and in
understanding drug metabolism and toxicity in CYP3A4.
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